CinCor Pharma

CINCINNATI, OH · Founded 2018 · CIK 0001868734 · Biotech · Private

Baxdrostat, an aldosterone synthase inhibitor small molecule therapeutic for resistant hypertension

cincor.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$143M
1 Form D · Oct 2021
60 months since last filing
Contracts
—
No federal contracts on record
Patents
11
0 granted · 11 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$142,864,996
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2840Scorpion Therapeutics—$297M
2841VASCULAR BIOSCIENCES, INC.——
2842EXPRESSION THERAPEUTICS, LLC——
2843CinCor Pharma—$143M
2844GRADIENT BIOMODELING, LLC——
2845Solid Biosciences—$109M
2846Lomond Therapeutics——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 1 related persons
  • Marc de GaridelDirector · Executive Officer

Patents

USPTO · 0 granted of 11
  • Method Of Treating Hypertension With The Aldosterone Synthase Inhibitor Baxdrostatapplication
  • Methods Of Using Aldosterone Synthase Inhibitorsapplication
  • Methods Of Using Aldosterone Synthase Inhibitorsapplication
  • Methods Of Using Aldosterone Synthase Inhibitorsapplication
  • Methods Of Using Aldosterone Synthase Inhibitorsapplication
  • Methods Of Using Aldosterone Synthase Inhibitorsapplication
  • Methods Of Using Aldosterone Synthase Inhibitorsapplication
  • Methods Of Using Aldosterone Synthase Inhibitorsapplication
  • Methods Of Using Aldosterone Synthase Inhibitorsapplication
  • Methods Of Treating Hypertension, Primary Aldosteronism, And Chronic Kidney Diseaseapplication
  • Methods For Using Aldosterone Synthase Inhibitorsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.